- Home
- MCRI vs EWTX Comparison
MCRI vs EWTX Comparison
Compare MCRI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- EWTX
- Stock Information
- Founded
- MCRI 1972
- EWTX 2017
- Country
- MCRI United States
- EWTX United States
- Employees
- MCRI N/A
- EWTX N/A
- Industry
- MCRI Hotels/Resorts
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- EWTX Health Care
- Exchange
- MCRI Nasdaq
- EWTX Nasdaq
- Market Cap
- MCRI 1.5B
- EWTX 1.2B
- IPO Year
- MCRI 1993
- EWTX 2021
- Fundamental
- Price
- MCRI $83.74
- EWTX $14.28
- Analyst Decision
- MCRI Hold
- EWTX Buy
- Analyst Count
- MCRI 5
- EWTX 8
- Target Price
- MCRI $88.60
- EWTX $40.13
- AVG Volume (30 Days)
- MCRI 84.8K
- EWTX 1.1M
- Earning Date
- MCRI 07-23-2025
- EWTX 05-08-2025
- Dividend Yield
- MCRI 1.43%
- EWTX N/A
- EPS Growth
- MCRI N/A
- EWTX N/A
- EPS
- MCRI 3.96
- EWTX N/A
- Revenue
- MCRI $525,923,000.00
- EWTX N/A
- Revenue This Year
- MCRI $4.32
- EWTX N/A
- Revenue Next Year
- MCRI $2.41
- EWTX N/A
- P/E Ratio
- MCRI $21.14
- EWTX N/A
- Revenue Growth
- MCRI 3.84
- EWTX N/A
- 52 Week Low
- MCRI $65.57
- EWTX $10.60
- 52 Week High
- MCRI $96.11
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- MCRI 62.61
- EWTX 43.22
- Support Level
- MCRI $80.40
- EWTX $13.80
- Resistance Level
- MCRI $85.16
- EWTX $14.68
- Average True Range (ATR)
- MCRI 1.53
- EWTX 0.78
- MACD
- MCRI 0.19
- EWTX 0.08
- Stochastic Oscillator
- MCRI 70.17
- EWTX 29.68
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.